Eagle Pharmaceuticals (EGRX) News Today $5.72 -0.02 (-0.35%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 24 at 3:43 AM | americanbankingnews.comEagle Pharmaceuticals (NASDAQ:EGRX) Receives New Coverage from Analysts at StockNews.comJuly 17, 2024 | americanbankingnews.comEagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated by Analysts at StockNews.comJuly 16, 2024 | marketbeat.comStockNews.com Initiates Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)StockNews.com began coverage on shares of Eagle Pharmaceuticals in a research report on Tuesday. They set a "hold" rating for the company.July 8, 2024 | marketbeat.comEagle Pharmaceuticals (NASDAQ:EGRX) Research Coverage Started at StockNews.comStockNews.com assumed coverage on Eagle Pharmaceuticals in a research report on Monday. They set a "hold" rating for the company.July 4, 2024 | marketbeat.comEagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Sees Large Decline in Short InterestEagle Pharmaceuticals, Inc. (NASDAQ:EGRX - Get Free Report) saw a significant drop in short interest in the month of June. As of June 15th, there was short interest totalling 994,400 shares, a drop of 7.9% from the May 31st total of 1,080,000 shares. Approximately 8.7% of the company's shares are sold short. Based on an average daily volume of 149,300 shares, the short-interest ratio is presently 6.7 days.June 18, 2024 | marketbeat.comEagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Sees Significant Decrease in Short InterestEagle Pharmaceuticals, Inc. (NASDAQ:EGRX - Get Free Report) saw a significant drop in short interest in May. As of May 31st, there was short interest totalling 1,080,000 shares, a drop of 5.3% from the May 15th total of 1,140,000 shares. Based on an average daily trading volume, of 151,900 shares, the short-interest ratio is presently 7.1 days. Currently, 9.5% of the company's stock are short sold.June 6, 2024 | marketbeat.comEagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by Analysts at StockNews.comStockNews.com began coverage on shares of Eagle Pharmaceuticals in a report on Thursday. They issued a "hold" rating for the company.May 22, 2024 | finanznachrichten.deEagle Pharmaceuticals, Inc.: Eagle Pharmaceuticals Announces Receipt of Delisting Notification from NasdaqMay 22, 2024 | globenewswire.comEagle Pharmaceuticals Announces Receipt of Delisting Notification from NasdaqMay 21, 2024 | marketbeat.comBrandes Investment Partners LP Lowers Stock Position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)Brandes Investment Partners LP reduced its position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX - Free Report) by 34.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 745,080 shares of the specialty pharmaceutical company's stApril 30, 2024 | finance.yahoo.comEagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual MeetingApril 15, 2024 | globenewswire.comEagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, FloridaApril 14, 2024 | investing.comEagle Pharmaceuticals faces potential Nasdaq delistingApril 13, 2024 | msn.comStocks Slightly Higher as US Mar PPI Climbs Less Than ExpectedApril 13, 2024 | msn.comStocks Mixed as Bond Yields ClimbApril 12, 2024 | finance.yahoo.comEagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-KApril 12, 2024 | globenewswire.comEagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-KFebruary 29, 2024 | msn.comEagle Pharmaceuticals to cut 36% of workforceFebruary 22, 2024 | benzinga.comEagle Pharmaceuticals Stock (NASDAQ:EGRX), Short Interest ReportFebruary 22, 2024 | benzinga.comEagle Pharmaceuticals Stock (NASDAQ:EGRX) Dividends: History, Yield and DatesFebruary 19, 2024 | marketbeat.comBrandes Investment Partners LP Boosts Stock Holdings in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)Brandes Investment Partners LP grew its position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX - Free Report) by 34.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,134,363 shares of the specialty pharmacFebruary 9, 2024 | prnewswire.comEAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their OptionsFebruary 8, 2024 | stockhouse.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)February 8, 2024 | markets.businessinsider.comLevi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc.(EGRX) of a Class Action Lawsuit and an Upcoming DeadlineFebruary 8, 2024 | markets.businessinsider.comShareholders that lost money on Eagle Pharmaceuticals, Inc.(EGRX) should contact Levi & Korsinsky about pending Class Action - EGRXFebruary 7, 2024 | markets.businessinsider.comClass Action Filed Against Eagle Pharmaceuticals, Inc. (EGRX) Seeking Recovery for Investors - Contact Levi & KorsinskyFebruary 6, 2024 | stockhouse.comSHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming DeadlineFebruary 2, 2024 | stockhouse.com7-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmFebruary 2, 2024 | barrons.comEGRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Eagle Pharmaceuticals, Inc. Shareholders to Contact the Firm!February 2, 2024 | marketbeat.comAssenagon Asset Management S.A. Has $3.43 Million Stock Position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)Assenagon Asset Management S.A. raised its position in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX - Free Report) by 66.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 217,February 1, 2024 | stockhouse.comINVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmFebruary 1, 2024 | marketbeat.comEagle Pharmaceuticals (NASDAQ:EGRX) Stock Price Passes Below Two Hundred Day Moving Average of $12.10Eagle Pharmaceuticals (NASDAQ:EGRX) Share Price Crosses Below Two Hundred Day Moving Average of $12.10February 1, 2024 | markets.businessinsider.comEGRX 9-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Eagle Pharmaceuticals (EGRX) Investors with Substantial Losses to Contact Firm Before Feb. 9th Deadline in Securities...January 31, 2024 | stockhouse.comINVESTOR ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - EGRXJanuary 31, 2024 | barrons.comINVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmJanuary 30, 2024 | stockhouse.comINVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmJanuary 30, 2024 | stockhouse.comSHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc. (EGRX) Investors of a Class Action Lawsuit and Upcoming DeadlineJanuary 28, 2024 | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Eagle Pharmaceuticals, Inc. - EGRXJanuary 28, 2024 | markets.businessinsider.comEagle Pharmaceuticals (EGRX) Tells SEC It Improperly Accounted for Past Two Quarters and Defaults on Lender Agreement - Hagens BermanJanuary 23, 2024 | investing.comEagle Pharmaceuticals Inc (EGRX)January 19, 2024 | markets.businessinsider.comSHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmJanuary 18, 2024 | finanznachrichten.deEagle Pharmaceuticals, Inc.: Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property PortfolioJanuary 18, 2024 | finance.yahoo.comEagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property PortfolioJanuary 14, 2024 | markets.businessinsider.comEagle Pharmaceuticals Deadline ReminderJanuary 11, 2024 | stockhouse.comSHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - EGRXJanuary 3, 2024 | msn.comSHAREHOLDER ALERT: Potential Recovery for Eagle Pharmaceuticals, Inc. (EGRX) InvestorsJanuary 2, 2024 | businesswire.comROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – EGRXDecember 31, 2023 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors in Eagle Pharmaceuticals, Inc. - EGRXDecember 22, 2023 | markets.businessinsider.comEagle Pharmaceuticals Shareholder Action ReminderDecember 22, 2023 | stockhouse.comFINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses to Contact the Firm Get Eagle Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Man Who Called Nvidia at $1.10 Says Buy This Now... (Ad)In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia. Watch Alex's "Next Magnificent Seven" presentation now. EGRX Media Mentions By Week EGRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EGRX News Sentiment▼0.960.62▲Average Medical News Sentiment EGRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EGRX Articles This Week▼32▲EGRX Articles Average Week Get Eagle Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: FHTX News ENTA News ADAP News RNAC News ADCT News AKBA News CRMD News ZVRA News ATAI News MRSN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EGRX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eagle Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eagle Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.